Valor pronóstico del descenso absoluto de la porción N-terminal del propéptido natriurético tipo B en insuficiencia cardiaca descompensada: análisis secundario del estudio CLUSTER-HF
Creators
- 1. Instituto Nacional de Salud del Niño
- 2. Instituto Nacional de Cardiología
- 3. Johns Hopkins University
- 4. Centro Medico Nacional Siglo XXI
- 5. Mexican Social Security Institute
Description
The purpose of this study is to determine the prognostic value of the absolute decrease in the N-terminal portion of pro-B-type natriuretic peptide (NT-proBNP) to prevent fewer clinical events, in the population of CLUSTER-HF (efficacy of ultrasound lung to guide therapy and prevent readmissions in heart failure).This study was conducted in a subgroup of ninety-four patients with available NT-proBNP information at hospital discharge and prior to randomization in the CLUSTER-HF study. The primary objective of the study was to determine the prognostic value of absolute NT-proBNP decline below which fewer events of all-cause death, emergency room visits, and rehospitalization for heart failure at 180 days.The absolute decrease in NT-proBNP below 3,350 pg/mL has a moderate discriminative capacity with AUC= 0.602, with a prognostic value in the combined event at 180 days (log-rank test, p=0.01). Also, according to the multivariable analysis, it is an independent marker of clinical events at 180 days OR 0.319 (0.102-0.995, p=0.04) above other clinical variables.An absolute decrease to 3,350 pg/mL of NT-proBNP or less at discharge from the hospitalization due to heart failure, was associated with fewer clinical events at 180 days.
Translated Descriptions
Translated Description (Arabic)
الغرض من هذه الدراسة هو تحديد القيمة التنبؤية للانخفاض المطلق في الجزء الطرفي N من الببتيد المدر للصوديوم من النوع Pro - B (NT - proBNP) لمنع عدد أقل من الأحداث السريرية، في سكان CLUSTER - HF (فعالية الموجات فوق الصوتية الطويلة لتوجيه العلاج ومنع إعادة الإدخال في فشل القلب). أجريت هذه الدراسة في مجموعة فرعية من أربعة وتسعين مريضًا لديهم معلومات NT - proBNP المتاحة عند الخروج من المستشفى وقبل التوزيع العشوائي في دراسة CLUSTER - HF. كان الهدف الأساسي من الدراسة هو تحديد القيمة التنبؤية لانخفاض NT - proBNP المطلق الذي تقل دونه أحداث أقل من الوفاة لجميع الأسباب، وزيارات غرفة الطوارئ، وإعادة المستشفى لفشل القلب في 180 يومًا. الانخفاض المطلق في NT - proBNP أقل من 3350 بيكوغرام/مل له قدرة تمييزية معتدلة مع AUC= 0.602، مع قيمة تنبؤية في الحدث المشترك في 180 يومًا (اختبار السجل، p=0.01). أيضًا، وفقًا للتحليل متعدد المتغيرات، فهو مؤشر مستقل للأحداث السريرية عند 180 يومًا أو 0.319 (0.102-0.995، p=0.04) أعلى من المتغيرات السريرية الأخرى. ارتبط الانخفاض المطلق إلى 3.350 بيكوغرام/مل من NT - proBNP أو أقل عند الخروج من المستشفى بسبب فشل القلب، بأحداث سريرية أقل عند 180 يومًا.Translated Description (English)
The purpose of this study is to determine the prognostic value of the absolute decrease in the N-terminal portion of pro-B-type natriuretic peptide (NT-proBNP) to prevent fewer clinical events, in the population of CLUSTER-HF (efficacy of ultrasound long to guide therapy and prevent readmissions in heart failure).This study was conducted in a subgroup of ninety-four patients with available NT-proBNP information at hospital discharge and prior to randomization in the CLUSTER-HF study. The primary objective of the study was to determine the prognostic value of absolute NT-proBNP decline below which fewer events of all-cause death, emergency room visits, and rehospitalization for heart failure at 180 days. The absolute decrease in NT-proBNP below 3,350 pg/mL has a moderate discriminative capacity with AUC= 0.602, with a prognostic value in the combined event at 180 days (log-rank test, p=0.01). Also, according to the multivariable analysis, it is an independent marker of clinical events at 180 days OR 0.319 (0.102-0.995, p=0.04) above other clinical variables. An absolute decrease to 3.350 pg/mL of NT-proBNP or less at discharge from the hospitalization due to heart failure, was associated with fewer clinical events at 180 days.Translated Description (French)
The purpose of this study is to determine the pronostic value of the absolute decrease in the N-terminal portion of pro-B-type natriuretic peptide (NT-proBNP) to prevent fewer clinical events, in the population of CLUSTER-HF (efficacy of ultrasound lung to guide therapy and prevent readmissions in heart failure).This study was conducted in a subgroup of ninety-four patients with available NT-proBNP information at hospital discharge and prior to randomization in the CLUSTER-HF study. The primary objective of the study was to determine the pronnostic value of absolute NT-proBNP decline below which fewer events of all-cause death, emergency room visits, and rehospitalization for heart failure at 180 days.The absolute decrease in NT-proBNP below 3,350 pg/mL has a moderate discriminative capacity with AUC= 0.602, with a pronnostic value in the combined event at 180 days (log-rank test, p=0.01). Also, according to the multivariable analysis, it is an independent marker of clinical events at 180 days OR 0.319 (0.102-0.995, p=0.04) above other clinical variables.An absolute decrease to 3,350 pg/mL of NT-proBNP or less at discharge from the hospitalization due to heart failure, was associated with fewer clinical events at 180 days.Files
275.pdf
Files
(299.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:8421e8c97bcd52165e74a18a242dade9
|
299.3 kB | Preview Download |
Additional details
Additional titles
- Translated title (Arabic)
- القيمة التنبؤية للانخفاض المطلق للجزء الطرفي N من بروبيبتيد مدر للصوديوم من النوع B في قصور القلب اللا تعويضي: تحليل ثانوي لدراسة CLUSTER - HF
- Translated title (English)
- Prognostic value of the absolute decrease of the N-terminal portion of the type B natriuretic propeptide in decompensated heart failure: secondary analysis of the CLUSTER-HF study
- Translated title (French)
- Valeur pronostique de la diminution absolue de la partie N-terminale du propeptide natriurétique de type B en insuffisance cardiaque décompensée : analyse secondaire de l'étude CLUSTER-HF
Identifiers
- Other
- https://openalex.org/W4224996556
- DOI
- 10.47487/apcyccv.v3i1.198
References
- https://openalex.org/W1911692366
- https://openalex.org/W1977687538
- https://openalex.org/W2009428581
- https://openalex.org/W201276026
- https://openalex.org/W2056745954
- https://openalex.org/W2066249273
- https://openalex.org/W2099769151
- https://openalex.org/W2119340816
- https://openalex.org/W2140980422
- https://openalex.org/W2154631043
- https://openalex.org/W2161643222
- https://openalex.org/W2219849670
- https://openalex.org/W2745438221
- https://openalex.org/W2772356304
- https://openalex.org/W2903905024
- https://openalex.org/W2944687799
- https://openalex.org/W2954240927
- https://openalex.org/W3006908074
- https://openalex.org/W3012582253
- https://openalex.org/W3034796407
- https://openalex.org/W3130061439
- https://openalex.org/W82015992